Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity
- PMID: 17525631
- DOI: 10.1097/01.pai.0000210418.38246.58
Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity
Abstract
The biologic behavior of neuroblastoma (NB) is extremely variable; therefore, the clinical behavior may be reliably predicted based on the analysis of a panel of prognostic parameters. High vascular density has been correlated with aggressive tumor progression in many types of cancers. The goal of this study was to correlate the tumor vascularity in NB with status of MYCN and the short arm of chromosome 1 (1p) to address the association between angiogenesis and genetic markers of prognostic significance. The study population consisted of 33 patients with histologically proven diagnosis of primary NB and no history of previous chemotherapy. Histologic quantitation of tumor angiogenesis was performed using 3 different methods: microvessel density, vascular grading, and Chalkley counting. MYCN amplification and 1p deletion were determined by using fluorescence in situ hybridization technique. The differentiation and mitosis-karyorrhexis index of tumor cells were also assessed using the Shimada System. MYCN amplification was present in 12 cases (36.3%), and 1p deletion in 16 (48.5%). Both genetic changes significantly correlated with increased tumor vascularity. In addition, tumor vascularity was significantly increased in tumors with high mitosis-karyorrhexis index or of undifferentiated histology. We conclude that angiogenesis shows close association with histologic and genetic prognosticators in NB. Our data support the validity of recent applications of antiangiogenic agents which interfere or block NB progression.
Similar articles
-
Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.Cancer Genet Cytogenet. 2007 Jan 15;172(2):113-9. doi: 10.1016/j.cancergencyto.2006.10.005. Cancer Genet Cytogenet. 2007. PMID: 17213019
-
Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.Diagn Mol Pathol. 2005 Sep;14(3):177-82. doi: 10.1097/01.pas.0000176767.10800.17. Diagn Mol Pathol. 2005. PMID: 16106200
-
FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.Med Pediatr Oncol. 2003 Jul;41(1):30-5. doi: 10.1002/mpo.10313. Med Pediatr Oncol. 2003. PMID: 12764740
-
Analysis of genomic imprinting at 1p35-36 in neuroblastoma.Med Pediatr Oncol. 2001 Jan;36(1):52-5. doi: 10.1002/1096-911X(20010101)36:1<52::AID-MPO1014>3.0.CO;2-8. Med Pediatr Oncol. 2001. PMID: 11464906 Review.
-
Risk estimation of neuroblastoma patients using molecular markers.Klin Padiatr. 2008 May-Jun;220(3):137-46. doi: 10.1055/s-2008-1065345. Klin Padiatr. 2008. PMID: 18478485 Review.
Cited by
-
Lymph microvascularization as a prognostic indicator in neuroblastoma.Oncotarget. 2018 May 25;9(40):26157-26170. doi: 10.18632/oncotarget.25457. eCollection 2018 May 25. Oncotarget. 2018. PMID: 29899849 Free PMC article.
-
Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors.Oncotarget. 2016 Apr 12;7(15):19935-47. doi: 10.18632/oncotarget.7661. Oncotarget. 2016. PMID: 26918726 Free PMC article.
-
Dynamic Changes in Microvascular Density Can Predict Viable and Non-Viable Areas in High-Risk Neuroblastoma.Cancers (Basel). 2023 Feb 1;15(3):917. doi: 10.3390/cancers15030917. Cancers (Basel). 2023. PMID: 36765874 Free PMC article.
-
Neuroblastoma and MYCN.Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a014415. doi: 10.1101/cshperspect.a014415. Cold Spring Harb Perspect Med. 2013. PMID: 24086065 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical